Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Onconova Therapeutic (NQ: ONTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Onconova Therapeutic < Previous 1 2 3 4 5 6 Next > Traws Pharma Announces New Employee Inducement Grants April 02, 2024 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company April 02, 2024 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024 March 08, 2024 Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics's Earnings: A Preview November 13, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session February 15, 2024 Via Benzinga Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket December 12, 2023 Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Via Benzinga Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma December 12, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session December 11, 2023 Via Benzinga Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session December 11, 2023 Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session December 11, 2023 Via Benzinga Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket December 11, 2023 Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday December 11, 2023 It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session December 08, 2023 Via Benzinga Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s December 08, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference November 28, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results November 14, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 November 07, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL November 02, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session October 31, 2023 Via Benzinga Onconova Expands Leadership Team with Two Key Appointments October 24, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Promising Preclinical Narazaciclib Data Presented at MCL Meeting October 19, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Encouraging Rigosertib Data Presented at EADV as Late Breaker October 12, 2023 Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need From Onconova Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session October 11, 2023 Via Benzinga Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress September 28, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results August 10, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023 August 03, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For August 10, 2023 August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. Via Benzinga Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma June 14, 2023 Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting June 05, 2023 Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa From Onconova Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.